Arcutis Biotherapeutics Inc

Healthcare · Biotechnology

26.90$ +2.5% vs. previous close Closing price · As of: Sep 25, 2026

Statements

Balance Sheet

Arcutis Biotherapeutics Inc (ARQT) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 489 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size %

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet ARQT
Line item	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Total Assets	–	–	–	51	38	38	28	107	254	232	198	298	471	433	387	408	364	300	509	449	379	321	293	341	479	445	437	349	344	352	371	433	460	489
Current Assets	3.4	–	–	51	51	38	28	106	254	228	194	293	466	428	382	403	359	295	497	437	368	309	282	330	468	435	424	336	324	333	349	411	438	468
Cash	-3.4	–	–	39	-51	13	23	63	191	172	46	65	289	91	53	98	71	62	82	54	81	105	107	88	191	85	135	71	53	73	47	43	35	34
Cash & Short-Term Investments	3.4	–	–	51	51	36	25	101	249	224	190	284	445	411	369	389	345	282	477	410	332	269	227	272	404	363	331	228	198	191	191	221	224	239
Receivables	–	–	–	–	–	–	–	–	–	–	0.5	0.5	0.6	0.4	0.4	0.4	0.4	–	2.4	8.5	13	17	19	26	37	43	60	73	85	107	115	146	144	155
Inventory	–	–	–	–	–	–	–	–	–	–	–	–	1.0	–	–	1.2	–	–	4.3	7.5	8.6	10	14	13	13	14	14	15	17	16	22	23	37	39
Property, Plant & Equipment	–	–	–	–	0.5	0.5	0.5	0.5	0.5	3.9	3.8	2.0	2.1	5.3	2.0	2.3	2.2	5.0	1.9	4.6	2.1	1.9	–	–	–	–	–	–	–	–	–	–	–	–
Intangible Assets	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	7.4	7.2	7.0	6.8	6.6	6.4	6.3	6.1	9.8	9.5	17	16	15	15	14	14
Total Liabilities	–	–	–	75	4.6	4.6	81	5.6	13	23	25	28	20	18	24	110	110	105	238	240	240	240	246	253	254	258	281	191	201	213	213	243	270	268
Current Liabilities	–	–	–	2.7	4.2	4.2	8.6	5.2	12	19	21	23	15	13	19	33	33	27	37	38	37	37	42	47	47	51	172	81	91	104	100	130	163	160
Short-Term Debt	–	–	–	–	–	0.2	0.2	0.2	0.2	0.1	0.0	–	–	0.1	0.3	0.4	0.5	0.6	0.6	0.7	0.7	0.7	0.7	0.7	0.8	0.8	100	0.8	0.8	1.0	1.0	1.0	8.0	7.0
Accounts Payable	–	–	–	1.8	2.0	2.0	3.2	1.4	4.8	8.3	5.0	7.1	3.1	2.7	4.9	7.4	12	8.4	8.7	8.8	12	17	13	12	13	7.9	19	14	25	15	5.8	13	18	6.6
Long-Term Debt	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	72	73	73	197	198	199	200	201	202	203	204	105	107	108	107	107	108	101	102
Shareholders' Equity	2.2	–	–	-24	48	34	-53	101	242	209	173	271	451	414	363	298	254	195	271	210	140	81	47	89	225	186	157	158	143	139	158	189	190	221
Retained Earnings	–	–	–	-24	-39	-39	-54	-66	-94	-130	-168	-202	-238	-280	-337	-408	-473	-540	-648	-720	-800	-871	-916	-982	-1,017	-1,070	-1,111	-1,122	-1,147	-1,163	-1,155	-1,138	-1,149	-1,134
Shares Outstanding	1.1	1.1	36	36	37	38	36	38	38	38	38	43	47	50	50	50	51	51	57	61	61	61	62	93	111	123	124	121	126	127	133	136	129	136

Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Balance Sheet

Cookie settings